A Double-blind Randomized Placebo Controlled Trial of Rabeprazole for Prevention of NSAID-associated Dyspepsia and Gastroduodenal Injury.

Trial Profile

A Double-blind Randomized Placebo Controlled Trial of Rabeprazole for Prevention of NSAID-associated Dyspepsia and Gastroduodenal Injury.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Rabeprazole (Primary)
  • Indications Duodenal ulcer; Dyspepsia; Gastric ulcer; NSAID-induced gastrointestinal damage
  • Focus Therapeutic Use
  • Acronyms RAN
  • Most Recent Events

    • 21 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Nov 2013 Planned number of patients changed from 160 to 112 as reported by ClinicalTrials.gov.
    • 04 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top